Finally, the rat experiment verified that AKT1 might be the main target of QSDH prescription in the treatment of MG, and QSDH prescription can play a role in the treatment of MG by inhibiting the PI3K/AKT signaling pathway. This evidence concerns the gene AKT1 and myasthenia gravis.